<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152308</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S01903</org_study_id>
    <nct_id>NCT00152308</nct_id>
  </id_info>
  <brief_title>Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis</brief_title>
  <official_title>A Prospective, Placebo-Controlled, Double-Blind, Randomized Study Evaluating the Efficacy of Non-Polymer-Based Coating With Two Different Rapamycin-Dosages for the Prevention of Restenosis After Percutaneous Coronary Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translumina GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translumina GmbH</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effectively of coating of coronary stents with
      two different doses of rapamycin for the prevention of coronary vessel re-blockage
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In-stent restenosis remains the major problem limiting the efficacy of coronary stenting.
      Either sirolimus or paclitaxel drug-eluting stents have been demonstrated to decrease
      neointima proliferation resulting in a remarkable reduction of restenosis rate. However,
      despite the outstanding results achieved with this novel approach to restenosis, some caveats
      still remain. Although sirolimus markedly decreased the restenosis rate among diabetic
      patients in SIRIUS trial, the benefit of treatment was modest in those diabetics treated with
      insulin as well as with lesions longer than 15 mm located in vessels smaller than 2.5 mm.
      Additionally, in a recent study it was reported that the restenosis rate in high-risk lesions
      such as coronary bifurcations still remains a problem Data from patient populations other
      than those enrolled in randomized trials suggest even more caution in the evaluation of the
      impact of DES on restenosis in the “real world”, where the operator must deal with in-stent
      restenosis, bifurcation lesions, chronic total occlusions, small vessels, and long lesions.
      The identification of some of the traditional risk factors for restenosis as important
      predictors for in-DES restenosis could be explained as an insufficient inhibition of tissue
      reaction and neointimal growth by the antiproliferative action of the specific drug or dose
      used. This leads to the inference that an individualized approach should be adopted by
      tailoring the choice and the dosing of eluting drug(s) according to the specific lesion or
      patient characteristics. On the other hand, although drug-eluting stents are currently
      considered as the most effective way to reduce in-stent restenosis, their widespread use is
      hampered by the high costs. Therefore, it is important to develop new methods and techniques
      that would result in a more effective prevention of in-stent restenosis while being available
      for a larger number of patients. These considerations as well as the proven efficacy of
      rapamycin in lowering the rate of coronary restenosis, support the rationality of the concept
      of on-site coating of stents in the catheterization laboratory with individualized doses of
      rapamycin after the clinical and the angiographic profiles of the patient scheduled to
      coronary stenting have been determined
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date>February 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binary angiographic restenosis at follow-up angiogram</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (all-cause death, myocardial infarction, or revascularization of the target lesion)</measure>
  </secondary_outcome>
  <enrollment>333</enrollment>
  <condition>Coronary Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2% rapamycin-eluting YUKONdes PEARL-stent</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1% rapamycin-eluting YUKONdes PEARL-stent</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YUKONdes PEARL-stent coated with placebo (ethanol)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18-85 years; Symptoms (stable or unstable angina) or signs of myocardial ischemia;
        Single de novo diagnosed lesion in a native coronary artery (50-99% DS); Lesion length 8 –
        25 mm; Vessel diameter 2.25-3.75 mm; Written informed consent

        Exclusion Criteria:

        Left main target lesion unprotected by a graft; Ostial and bifurcation target lesion;
        Severely calcified lesions; Thrombus in target lesion; Tortuosity or angulation of target
        vessel or lesion; Treatment of nontarget lesions in the same or a different coronary vessel
        during the index procedure; Contraindications to the study medications; Acute myocardial
        infarction (&lt; 48 h); Left ventricular ejection fraction &lt; 25%; Participation in another
        trial; Pregnancy or lack of protection against pregnancy during the study Coexisting
        conditions limiting the life expectancy to less 24 months or that could affect the
        compliance of patients with protocol; Serum creatinin &gt;2.0mg/dL; Hemorrhagic diathesis;
        Leukocyte count &lt;3500/ml^3 Platelet count &lt;100.000/ml^3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schomig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Huber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wilhelminenspital der Stadt Wien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gisela Schoemig</last_name>
    <phone>+49 89 2102 8920</phone>
    <email>Gisela.Schoemig@translumina.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Johanns Spital</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Heigert, MD</last_name>
      <email>M.heigert@salk.at</email>
    </contact>
    <investigator>
      <last_name>Mathias Heigert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Donauspital der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Norman, MD</last_name>
      <phone>+43 1 28802</phone>
    </contact>
    <investigator>
      <last_name>Georg Norman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietmar Glogar, MD</last_name>
      <email>helmut-dietmar.glogar@univie.ac.at</email>
    </contact>
    <investigator>
      <last_name>Dietmar Glogar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Huber, MD</last_name>
      <phone>+43 1 49150 0</phone>
      <email>kurt.huber@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Kurt Huber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adnan Kastrati, MD</last_name>
      <phone>+49 89 1218 4577</phone>
      <email>kastrati@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Adnan Kastrati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kardiologische Praxis und Praxisklinik</name>
      <address>
        <city>Munich</city>
        <zip>81379</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigmund Silber, MD</last_name>
      <phone>+49 89 742 15130</phone>
      <email>sigmund@silber.com</email>
    </contact>
    <investigator>
      <last_name>Sigmund Silber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Medizinische Klinik rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef , Dirschinger</last_name>
      <phone>+49 89 4140 2947</phone>
      <email>dirschinger@med1.med.tu-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Josef Dirschinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaim Lotan, MD</last_name>
      <email>Lotan@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Chaim Lotan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hylton Miller, MD</last_name>
      <email>himiller@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Hylton Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Krakover, MD</last_name>
      <phone>+972 08 9779738</phone>
    </contact>
    <investigator>
      <last_name>Ricardo Krakover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schömig A; investigators of the individualizable durg-eluting Stent System to Abrogate Restenosis Project. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005 Aug;26(15):1475-81. Epub 2005 Jun 23.</citation>
    <PMID>15975990</PMID>
  </reference>
  <reference>
    <citation>Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002 Jun 6;346(23):1773-80.</citation>
    <PMID>12050336</PMID>
  </reference>
  <reference>
    <citation>Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Müller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003 Feb 4;107(4):559-64.</citation>
    <PMID>12566366</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>September 8, 2005</last_update_submitted>
  <last_update_submitted_qc>September 8, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

